Vulvar Cancer Therapeutics Market Size, Share, and Industry Analysis, By Type (Drugs and Vaccines), By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma and Others), By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others), By Route of Administration (Oral, Parenteral and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government & Organizational Suppliers, and Others), and Regional Forecast, 2026-2034

The vulvar cancer therapeutics market is rising rapidly. Vulvar cancer affects the external female genitalia, primarily occurring in women over the age of 60 years. The leading factors causing vulvar cancers include human papillomavirus (HPV) infections, chronic inflammatory conditions, immunosuppression, and genetic predisposition. The cancer often exhibits symptoms of itching, pain, or visible lesions. The rising burden of vulvar cancer, coupled with limited adoption of HPV vaccination programs, is expected to drive the growth of the market with an upward trajectory over the forecast period. 

Furthermore, to promote research and development of various therapeutics for vulvar cancer, various key operating players in the market are directing their resources toward investment and funding opportunities—such developments are expected to boost the growth of global vulvar cancer therapeutics.

• For instance, in February 2025, Wellbeing of Women announced investment of USD 1.3 million into 18 new projects spanning across menstrual and sexual health, pregnancy, fertility and contraception, and gynecological cancers, including vulva cancers.

Vulvar Cancer Therapeutics Driver

Rising Prevalence of Vulvar Cancer to Heighten Demand for Therapeutics and Boost Market Growth

The rising prevalence of vulvar cancer, particularly among the older population of women due to higher HPV exposure, is expected to drive the growth of the market. Due to rising prevalence, there is a growing demand for cancer therapeutics, including targeted therapy and immunotherapies. Increasing prevalence encourages various pharmaceutical companies to invest profoundly in research and development to develop more advanced and safer therapeutic alternatives.

Furthermore, the growing focus on women’s health and government-backed cancer programs enhances patient access and treatment uptake. Such factors are expected to drive the market growth.

• For instance, in 2022, the Global Cancer Observatory reported an incidence of 47,336 cases of vulvar cancer globally.

Share of Estimated Number of Prevalent Cases of Vulvar Cancer, By Region, 2022

In 2022, the Global Cancer Observatory reported the highest prevalence in Europe, with15,006 prevalent cases and accounting for 40.6% global cases.

Vulvar Cancer Therapeutics Restraint

High Cost of Advanced Therapies Limits Access and Restricts Market Growth

One of the major factors restricting the growth of the market is the high cost, which limits access to novel therapies for patients. Poor reimbursement scenario in emerging economies such as the Asia Pacific and Europe further discourages product adoption. Many novel targeted therapies and immunotherapies carry high costs, and without insurance or national health coverage. This barrier directly impacts market growth by limiting sales volumes and slowing the uptake of novel therapeutics, despite clinical advancements.

• For instance, in 2025, the Comparator Report on Cancer in Europe reported that the total health expenditure tripled from USD 671.00 in 1995 to 2,398.27 billion in 2023. Such factors limit the access and hamper the growth potential of the vulvar cancer therapeutics market.

Vulvar Cancer Therapeutics Opportunity

Increasing Availability of New Targeted Medicines to Offer Lucrative Growth Opportunities

Ongoing research and clinical trials for the development of effective and targeted therapies for vulvar cancer offer a lucrative growth opportunity to the market. These therapies, ranging from immune checkpoint inhibitors to antibody-drug conjugates, not only offer higher precision but also minimal side effects, making them highly desirable for both patients and clinicians. Additionally, the expansion of these therapies into emerging markets bridges access gaps and supplements the treatment market for vulvar cancer with more effective alternatives.

• For instance, in May 2023, Alpha Tau Medical Ltd reported that a novel clinical trial study examining the safety and feasibility of intratumoral diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of new and recurrent squamous cell carcinoma was conducted. The trial successfully treated its first vulva patient at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust in Cambridge, England.

Key Insights

The report covers the following key insights:

• Prevalence of Vulvar Cancer, Key Countries/Regions, 2024
• Pipeline Analysis, By Key Players
• Reimbursement Scenario, Key Countries/ Regions
• Overview: Palliative Care for Vulvar Cancer
• Key Industry Development (Mergers, Acquisitions, Partnerships, etc.)
• New Product Launches, By Key Players

Segmentation

Analysis by Type

On the basis of the type, the market is classified into drugs and vaccines. Among these, vaccines are expected to hold a significant market share in the upcoming years. The high share of the vaccine is due to cost advantages attributed to the prevention of the diseases. Due to these advantages, the vaccine segment is expected to growth. Also, massive immunization programs to protect against vulvar cancer by HPV infection are expected to support the growth of the segment.

• For instance, in November 2024, the Lao People's Democratic Republic Ministry of Health, partnered with UNICEF, the World Health Organization (WHO), and Gavi, the Vaccine Alliance, the Government of Australia, and launched the human papillomavirus (HPV) immunization campaign. This initiative aimed to protect over 124,000 girls aged 10–14 from cervical and vulvar cancer.

Analysis by Cancer Type

Based on cancer type, the vulvar cancer therapeutics market is further divided into vulvar squamous cell carcinoma, vulvar melanoma, and others. The vulvar squamous cell carcinoma segment is expected to account for a significant market share in the global market. The high share of the segment is due to the high prevalence of vulvar squamous cell cancer—such factors drive the market growth. 

• For instance, in 2022, Cancer Research U.K. reported that squamous cell carcinoma is the most common type of vulvar cancer. It reported that in every 100 vulvar cancers, 90 were of this type. Such factors drive the growth of the segment in the market. 

Analysis by Product Type

On the basis of product type, the global market is classified into chemotherapy, immunotherapy, targeted therapy, and others. The chemotherapy segment is expected to hold a significant share in the segmental distribution. Chemotherapies are being used ubiquitously for the treatment of vulvar cancer. 

• For instance, in August 2021, NIH published an article titled ‘Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?’ reported that over the last 20 years, chemotherapy has been used in the treatment of vulvar cancer at multiple stages. 

Analysis by Route of Administration

Based on route of administration, the vulvar cancer therapeutics market is further divided into oral, parenteral, and others. Among which parenteral routes of administration is expected to lead the segmental growth. All the therapeutic alternatives, such as chemotherapy, immunotherapy, and targeted therapy, are most parenterally administered. Due to such factors, the parenteral route of administration is expected to drive the market growth. Also, the most prominent vaccine indicated for the prevention of vulva cancer, such as HPV, is administered parenterally.

• For example, GARDASIL 9, a vaccine indicated in girls and women for the prevention of the Cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers caused by Human Papillomavirus (HPV) types, is administered parenterally, i.e., via subcutaneous injection.

 Analysis by Distribution Channel

On the basis of the distribution channel, the market is divided into hospital & retail pharmacies, government & organizational suppliers, and others.

Government & organizational suppliers are expected to hold a significant market share. These government and organizational suppliers schedule mass vaccination programs to protect against vulvar and cervical cancer caused by HPV.

• For instance, in June 2025, under the Mukhyamantri Balika Cancer Pratirakshan Yojana (MBCPY), mass vaccination was organized in Patna, India, to protect young girls between the ages of 9 and 14 years from vulvar cancers.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America is estimated to dominate the global vulvar cancer therapeutics market—the region witnesses higher incidences of vulvar cancer due to higher exposure to HPV infections. To combat the rising prevalence of vulvar cancer, many key players are operating in the region. Along with them robust healthcare infrastructure, reimbursement opportunities are some of the factors contributing to the high regional share.

• For instance, in May 2025, the American Cancer Society estimated that about 7,480 cancers of the vulva would be diagnosed in the U.S.

Europe is projected to account for a considerable market share over the forecast period. The high market share of the region is attributed to increasing demand for vulvar cancer therapeutics due to an aging population, reimbursement drive, research and development, along with a massive vaccination drive organized by the government to combat HPV infection, the leading cause of vulvar cancer.

• For instance, in April 2025, Bulgaria’s Council of Ministers expanded national HPV vaccination to prevent cancers caused due to human papillomavirus (HPV). The vaccination drive is expected to protect from at least six types of cancer – cervical, vaginal, vulvar, anal, penile, and head & neck. Such a massive vaccination drive is expected to boost the demand for vulva therapeutics and support market growth.

Asia Pacific is expected to grow with a substantial CAGR during the forecast period. The regional growth is attributed to the rising healthcare expenditure in the region and strategic collaboration among key players to provide vulva cancer therapeutics. Such factors drive the growth of the market in the region.

Key Players Covered

The global vulvar cancer therapeutics market is semi-consolidated, with the presence of a few established companies and several other mid-size companies offering diverse product offerings.

The report includes the profiles of the following key players:

• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Sanofi S.A. (France)
• F. Hoffmann-La Roche Ltd (Switzerland) 
• AstraZeneca PLC (U.K.)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Novartis AG (Switzerland)
• Inovio Pharmaceuticals, Inc. (U.S.)
• GSK plc (U.K.)

Key Industry Developments

• In March 2024, Merck & Co., Inc., initiated clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types. The vaccine is indicated for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers caused by HPV in the U.S.
• In September 2022, GSK plc. discontinued the cervical cancer vaccine in India as part of portfolio rationalization efforts.